Hyperemesis Gravidarum Clinical Trial
Official title:
Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum
Verified date | February 2023 |
Source | State University of New York at Buffalo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators will compare the effectiveness of gabapentin to metoclopramide for 1 week among 60 women with hyperemesis gravidarum (HG) in this randomized, double-blinded trial. After completion of the 1-week double-blind phase, subjects will be offered open-label gabapentin with rescue metoclopramide until their symptoms no longer require treatment. Enrollment will occur at the University's at Buffalo, of Rochester and of Wisconsin.
Status | Completed |
Enrollment | 31 |
Est. completion date | November 2019 |
Est. primary completion date | October 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Have received at least 2 administrations of intravenous (iv) hydration separated by at least 1 week or daily emesis for at least the last 14 days and 1 administration of iv hydration. 2. Have at least one of the following: 2-4+ ketonuria, serum potassium < 3.4mmol, or >5% weight loss from weight upon entry to prenatal care. 3. Have failed therapy with at least one antiemetic. 4. Have fetal ultrasound within 6 weeks prior to enrollment confirming a normal-appearing, intrauterine, singleton pregnancy of gestational age < 16 weeks at time of enrollment. 5. Felt by the patient's obstetrician or emergency room attending physician not to have other medical problems such as bowel obstruction, pancreatitis, biliary colic, or peptic ulcer disease that could be contributing to the patient's symptoms. 6. Be >18 years old and not decided to terminate the pregnancy. 7. Have not received or planning to receive a peripherally inserted central catheter (PIC line). 8. Have a Motherisk-PUQE score of =12 for the 24-hour Baseline period. 9. Felt not to have any other significant medical, psychiatric or substance abuse problem that would preclude participation in the study. 10. Denies drinking any alcohol after learning about current pregnancy. 11. Agrees to discontinue any current anti-emetic treatments (including antihistamines, ginger, > 10mg/day vitamin B6, serotonin or dopamine antagonists, anticholinergics, acupuncture, hypnosis, or wrist bands) for the next 4 weeks. 12. Pregnancy not conceived through in-vitro fertilization. 13. Able to understand and comply with the study procedures and give informed consent. Exclusion Criteria: None not mentioned under Inclusion Criteria. |
Country | Name | City | State |
---|---|---|---|
United States | University at Buffalo | Buffalo | New York |
United States | University of Rochester | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
State University of New York at Buffalo | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Guttuso T Jr, Robinson LK, Amankwah KS. Gabapentin use in hyperemesis gravidarum: a pilot study. Early Hum Dev. 2010 Jan;86(1):65-6. doi: 10.1016/j.earlhumdev.2009.11.003. Epub 2009 Dec 16. — View Citation
Guttuso T Jr. Gabapentin's anti-nausea and anti-emetic effects: a review. Exp Brain Res. 2014 Aug;232(8):2535-9. doi: 10.1007/s00221-014-3905-1. Epub 2014 Mar 26. — View Citation
Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):599-606. doi: 10.1002/bdra.23028. Epub 2012 Jun 22. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7 | Score range: 6-30 with higher score indicating a worse outcome. | 1 week | |
Secondary | Baseline Adjusted Mean Daily Nausea Scores From the Motherisk-PUQE for Days 5-7. | Score range: 2-10 with higher score indicating a worse outcome. | 1 week | |
Secondary | Baseline Adjusted Mean Daily Oral Nutrition Score for Days 5-7 | Score range: 0-15 with higher score indicating a better outcome. | 1 week | |
Secondary | Percent of Subjects Requiring Repeat iv Hydration or Hospital Admission for HG From the Outpatient Setting. | 1 week | ||
Secondary | Global Satisfaction of Treatment at the Study Endpoint. | Score range: 0-4 with higher score indicating a better outcome. | 1 week | |
Secondary | Desire to Continue Therapy at Study Endpoint | Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome. | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04785911 -
Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Completed |
NCT04719286 -
MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy
|
N/A | |
Completed |
NCT02300155 -
Improving Multivitamin Supplementation to Pregnant Women
|
Phase 4 | |
Completed |
NCT05175079 -
Acupressure in Hyperemesis Gravidarum
|
N/A | |
Completed |
NCT05098067 -
Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
|
Phase 2 | |
Completed |
NCT01836835 -
Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian
|
N/A | |
Completed |
NCT03950167 -
Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum
|
||
Completed |
NCT02830321 -
The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women
|
N/A | |
Completed |
NCT02541682 -
Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy
|
N/A | |
Terminated |
NCT03785691 -
Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum
|
Phase 2 | |
Completed |
NCT05446025 -
The Levels of the Orexin, Galanin and aMSH and CART in Patients With Hyperemesis Gravidarum
|
||
Recruiting |
NCT02862496 -
Bone Health in Hyperemesis Gravidarum
|
N/A | |
Terminated |
NCT05452174 -
Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06442813 -
Effects Of Emotional Freedom Technique and Hypermesis Gravidarum
|
N/A | |
Completed |
NCT06245811 -
Inflammation Markers in Hyperemesis Gravidarum
|
||
Recruiting |
NCT06266819 -
The Effect of Mint Flavored Chewing Gum on Hyperemesis Gravidarum Nausea Vomiting Severity, Coping With Stress and Anxiety Level in Pregnants With Hyperemesis Gravidarum
|
N/A | |
Completed |
NCT04828967 -
Use of Hypnosis in Hyperemesis Gravidarum
|
N/A | |
Completed |
NCT03127293 -
Hyperemesis Gravidarum and Osteoporosis
|
N/A | |
Completed |
NCT01559012 -
Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum
|
Phase 3 |